This study is designed to evaluate the effectiveness of the current ticagrelor risk minimisation strategy in Canada through a prescriber knowledge and understanding (KAU) survey of selected important identified safety concerns (i.e., bleeding, dyspnea and drug interactions) and ASA dosage.
Effectiveness of risk minimisation interventions for ticagrelor in Canada
Study Type
OBSERVATIONAL
Enrollment
244
Research Site
Montreal, Quebec, Canada
KAU Questionnaire: Knowledge of the 4 key safety issues pertaining to ticagrelor (adequate or inadequate for each safety issue)
Time frame: 2 months
KAU Questionnaire: Practice characteristics
Time frame: 2 months
KAU Questionnaire: The difference in knowledge of understanding across the key safety concerns
Time frame: 2 months
KAU Questionnaire: Association between prescribers' characteristics and knowledge and understanding of the key safety concerns.
Time frame: 2 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.